Browse Studies — Arctuva

Phase 1

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin,…

Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+6 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT04375631

Phase 1

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.

Refractory Acute LeukemiaRelapsed Acute LeukemiaUndifferentiated Leukemia+1 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06466395

Phase 1

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain…

Refractory Acute LeukemiaPediatric Relapsed

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06397027

Phase 1

A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07356154